Canadians Have One of the World's Highest Rates of Multiple Sclerosis

The country to the north does not know why so many of its citizens develop relapse-remitting multiple sclerosis

Thursday, May 28, 2020 - Canada has one of the highest percentages of citizens with multiple sclerosis therefore the country is interested in understanding the disease better than most. Researchers do not know what causes multiple sclerosis. Ottawa Matters.com recently wrote an essay about what it is like to live with the disease as May is Multiple Sclerosis Awareness Month and the publication interviewed a young RRMS patient to get her thoughts on her personal experience living with the disease. Lemtrada stroke lawsuit claims continue to be filed by people harmed from the side effects of the drug Lemtrada and the following is a review of that article.

The Ottawa Matters essay describes a time in the life of a young woman age 23 who one day started to feel tingling in her hand and became concerned when the sensation would not stop and started to spread up her arm. Doctors initially thought she just had a pinched nerve from doing yoga but the young lady knew that she didn't feel right. The uncomfortable sensations quickly spread from her hand to arm, to her shoulder and then neck, and then to her head causing vision and balance issues. Still, doctors thought that a pinched nerve was to blame and it wasn't until the woman told her doctors that she was having difficulties with her balance and was falling over occasionally did they think to perform an MRI, which revealed brain lesions and led to her Multiple Sclerosis diagnosis. Over the first year, the MS spread quickly and the young woman suffered flare-ups of fatigue, memory fog, and forgetfulness, leading her to feel hesitant to speak out loud to others.

According to Ottowa Matters, relapse-remitting multiple sclerosis (RRMS) is a condition where protective nerve coverings called myelin are destroyed resulting in extreme sensitivity and firing off unexpectedly due to inflammation. While RRMS is not fatal, many die as a result of other complications resulting from having the disease, and RRMS sufferers have a shorter life expectancy than others. The average age of an RRMS patient is 32 years old, and the onset of the disease usually occurs between the age of 20-49 years of age. Infections resulting in death is common. Because of the sporadic nature of the RRMS flare-ups, it is usually difficult to tell if a person has the disease, and most people do not require a walking-assistance device. RRMS affects the central nervous system and every motor function the brain controls.

RRMS sufferers in the most advanced and desperate stages have turned to a drug that is highly effective in managing their symptoms yet can be extremely deadly. Lemtrada Alemtuzumab treatments are administered once per year in several doses for two weeks, over two years and side effects have included causing paralyzing strokes and instant death from a heart attack. Most severe symptoms from the medication occur within 72 hours of the initial intravenous infusion. Lemtrada's potential for causing life-threatening side effects are so likely that doctors administering the drug must co-sign a risk management disclosure statement with patients before prescribing treatment. Also, emergency medical personnel and equipment must be present to provide first aid, and hospital care should an event occur.

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
• MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
• Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
• Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
• Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
• People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
• Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
• Lemtrada Patients Have May Have Safer Options | 12/8/2020
• Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
• Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
• Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
• Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
• Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
• Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
• Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
• Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
• Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
• Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
• Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
• RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
• New Information About COVID19 and Taking Lemtrada | 7/16/2020
• The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
• Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
• A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
• Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
• RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
• Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
• Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
• Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
• Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
• Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
• Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
• Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
• Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
• Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
• Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
• Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
• Lemtrada Fears May Be Overdone | 1/30/2020
• Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
• One Last Lemtrada Warning for 2019 | 1/2/2020
• RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
• Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
• Lemtrada Side Effect Awareness Requirements | 12/11/2019
• Lemtrada is serious medication for a serious condition | 11/21/2019
• More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
• RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
• Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
• Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
• Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
• Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
• RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
• Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
• Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
• Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
• Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
• Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
• Lemtrada Patients Report Promising Results | 8/1/2019
• The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
• What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
• Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
• Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
• Treating Multiple Sclerosis From Many Angles | 6/21/2019
• Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
• A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
• A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
• Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
• The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
• Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
• The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
• The Pros and Cons of Lemtrada Therapy | 4/19/2019
• Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
• Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
• MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
• Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
• Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
• Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.